Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) said its fourth-quarter earnings rose 19% on stronger revenue, led by its specialty medicines. Teva is known mostly for selling generic drugs but also markets a number of patent-protected, branded medicines. The Israeli company is facing expected generic competition for its top-selling drug, multiple-sclerosis therapy Copaxone. The company also has been striving to cope with competition from lower-priced generic medicines from rival drug makers in India, which have been squeezing margins on Teva’s already-low-margin generic drugs. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock opened at $44.50 in last trading session, and closed at $45.39, trading in the range of $44.12 – $45.43. The stock showed a positive weekly performance of 0.98%.
Amarin Corporation plc (ADR) (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin’s President and Chief Executive Officer, is scheduled to present a general company update at the 2014 Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York City on Thursday, February 13, 2014, at 11:10 a.m. ET. Amarin Corporation plc (ADR) (NASDAQ:AMRN) shares closed at $1.83 on last trade day, by losing -5.18%. Stock 52 week range is $1.36 – $8.98. Company’s market capitalization is $315.94 billion.
Novo Nordisk A/S (ADR) (NYSE:NVO) to reinforce its equity stake in Innate Pharma * Anti-nkg2a is a first-in-class therapeutic mab that is phase II ready * Novo nordisk will receive 2 million euros in cash and 600,000 shares for licencing anti-nkg2a to Innate * Novo eligible to a total of 20 million euros in potential milestones and single-digit tiered royalties on future sales. Novo Nordisk A/S (ADR) (NYSE:NVO) stock advanced 3.71% and finished the last session at $41.05. The EPS of the stock remained 1.36. Company’s market capitalization is $109.01 billion.
Pernix Therapeutics Holdings (NYSE:PTX) major shareholder Cooper C. Collins unloaded 90,000 shares of the stock on the open market in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $2.22, for a total transaction of $199,800.00. Following the completion of the transaction, the insider now directly owns 6,180,046 shares of the company’s stock, valued at approximately $13,719,702. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) stock opened at $2.36 in last trading session and closed at $3.53. The 52 week range of the stock is $1.68 – $8.34 and the day range was $2.32 – $3.89.
Leave a Reply